Solid Biosciences Inc.

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

Solid Biosciences Announces Oversubscribed $240 Million Private Placement